ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AMP Amphion Innovations Plc

0.15
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Amphion Innovations Plc LSE:AMP London Ordinary Share GB00B0DJNP99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.15 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Amphion Innovations PLC Partner Company releases positive clinical results

05/10/2017 7:00am

RNS Non-Regulatory


TIDMAMP

Amphion Innovations PLC

05 October 2017

Amphion Innovations plc

("Amphion" or "the Company")

Amphion Partner Company, Motif Bio, Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study

   --     Iclaprim met the primary endpoint 
   --     Iclaprim was well tolerated in the study 
   --     NDA submission expected in the first quarter of 2018 

Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, comments on Partner Company Motif Bio plc ("Motif", AIM: MTFB, NASDAQ: MTFB) following positive topline results from its REVIVE-2 trial, a global Phase 3 clinical trial evaluating Motif's lead investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI), as announced 4 October 2017.

Amphion owns 14.1% of Motif Bio's issued share capital.

Richard Morgan, CEO of Amphion Innovations commented: "We are pleased that Motif Bio's lead antibiotic, iclaprim, has now successfully completed both of its Phase III trials. Yesterday, Motif Bio announced the topline data for REVIVE-2, the second of the two trials, which showed that iclaprim achieved the primary endpoint of non-inferiority compared to vancomycin, the current standard of care, at the early time point (ETP), and also achieved non-inferiority at the test of cure endpoint, 7 to 14 days after study drug discontinuation. Combined with the positive topline data for REVIVE-1, as announced 18 April 2017, Motif Bio is on track to submit a New Drug Application to the US FDA for iclaprim in the first quarter of 2018. Amphion owns 14.1% of Motif Bio, and we continue to believe that Motif Bio is not fully valued compared to other comparable antibiotic companies at the same stage of development."

For further information please contact:

 
 Amphion Innovations         Tel: +1 (212) 210 6224 
 Charlie Morgan 
 
 Walbrook PR               Tel: +44 (0)20 7933 8780 
                                                 or 
 Mike Wort/ Paul McManus     amphion@walbrookpr.com 
 
 

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXELEDLXFFF

(END) Dow Jones Newswires

October 05, 2017 02:00 ET (06:00 GMT)

1 Year Amphion Innovations Chart

1 Year Amphion Innovations Chart

1 Month Amphion Innovations Chart

1 Month Amphion Innovations Chart

Your Recent History

Delayed Upgrade Clock